U.S. Food and Drug Administration issues Complete Response
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for...
Source: globenewswire.com
Stay updated with breaking news from Persistent Hypoglycemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for...
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand...